Sucampo plans mid-year US filing for lubiprostone in opioid-induced bowel dysfunction
This article was originally published in Scrip
Executive Summary
Sucampo Pharmaceuticals says the company now has the long-term data it needs to support a supplemental new drug application (sNDA) to the US FDA for its drug lubiprostone to treat opioid-induced bowel dysfunction (OBD) in patients with chronic non-cancer-related pain.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.